|
|
|
Volumn 15, Issue 11, 2011, Pages 1355-1356
|
|
Grouping of molecularly targeted anti-cancer agents based on cost-effectiveness analysis
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CETUXIMAB;
ERLOTINIB;
FLUOROURACIL;
FOLINIC ACID;
GEFITINIB;
IMATINIB;
OXALIPLATIN;
RITUXIMAB;
TRASTUZUMAB;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER PATIENT;
CHRONIC MYELOID LEUKEMIA;
COLORECTAL CANCER;
COST EFFECTIVENESS ANALYSIS;
DRUG APPROVAL;
DRUG COST;
DRUG EFFICACY;
DRUG SAFETY;
ECONOMIC EVALUATION;
GASTROINTESTINAL STROMAL TUMOR;
GASTROINTESTINAL TUMOR;
HEALTH CARE POLICY;
HUMAN;
KIDNEY CANCER;
LETTER;
LUNG CANCER;
LUNG NON SMALL CELL CANCER;
LYMPHOMA;
MOLECULARLY TARGETED THERAPY;
ONCOLOGY;
OVERALL SURVIVAL;
PATIENT CARE;
PRACTICE GUIDELINE;
PROGNOSIS;
PROGRESSION FREE SURVIVAL;
RISK FACTOR;
TREATMENT DURATION;
TREATMENT RESPONSE;
COST BENEFIT ANALYSIS;
ECONOMICS;
NEOPLASM;
SURVIVAL;
ANTINEOPLASTIC AGENTS;
COST-BENEFIT ANALYSIS;
HUMANS;
MOLECULAR TARGETED THERAPY;
NEOPLASMS;
SURVIVAL;
|
|
EID: 84856021290
PISSN: 11283602
EISSN: None
Source Type: Journal
DOI: None Document Type: Letter |
|
Times cited : (14)
|
|
References (11)
|
